The estimated Net Worth of Michael H Carrel is at least $20.1 Million dollars as of 10 February 2021. Mr. Carrel owns over 75,000 units of Atricure Inc stock worth over $14,251,486 and over the last 12 years he sold ATRC stock worth over $0. In addition, he makes $5,829,780 as President, Chief Executive Officer, and Director at Atricure Inc.
Michael has made over 17 trades of the Atricure Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 75,000 units of ATRC stock worth $1,578,000 on 10 February 2021.
The largest trade he's ever made was exercising 125,249 units of Atricure Inc stock on 17 December 2020 worth over $1,878,735. On average, Michael trades about 9,459 units every 8 days since 2012. As of 10 February 2021 he still owns at least 529,795 units of Atricure Inc stock.
You can see the complete history of Mr. Carrel stock trades at the bottom of the page.
Michael H. Carrel serves as President, Chief Executive Officer, Director of the Company. Mr. Carrel has served as President, Chief Executive Officer and director since November 2012. Since joining AtriCure, Mr. Carrel has fostered a patient-first company approach by focusing on the three core areas: innovation, clinical science and education. This strategic approach has led AtriCure to significantly invest in groundbreaking clinical trials for the treatment of atrial fibrillation (Afib), left atrial appendage management and pain management; expand its market presence within Europe and Asia; and grow the global employee base from 200 to over 700 employees. In addition, during Mike’s tenure, AtriCure has acquired three companies, Estech, nContact, and SentreHEART, adding leading ablation and appendage management technologies to further AtriCure’s market position worldwide. Before joining AtriCure, Mr. Carrel served as President and Chief Executive Officer of Vital Images, a publicly-traded medical imaging software company that was sold to Toshiba in 2011. Prior to Vital Images, Mr. Carrel was President and CEO of Zamba Corporation, a publicly-traded technology company, and Chief Financial Officer of NextNet Wireless, a privately-held provider of non-line-of-sight plug and play broadband wireless access systems. Mr. Carrel recently served as a director of Lombard Medical until acquired by MicroPort Scientific Corporation in 2018. Mr. Carrel currently serves on the board of the Medical Device Manufacturers Association (MDMA) and Axonics Modulation Technologies, Inc. a medical device company focused on the treatment of urinary and bowel dysfunction. Mr. Carrel holds a B.S. in Accounting from The Pennsylvania State University and an M.B.A. from The Wharton School at the University of Pennsylvania.
As the President, Chief Executive Officer, and Director of Atricure Inc, the total compensation of Michael Carrel at Atricure Inc is $5,829,780. There are no executives at Atricure Inc getting paid more.
Michael Carrel is 49, he's been the President, Chief Executive Officer, and Director of Atricure Inc since 2012. There are 11 older and 1 younger executives at Atricure Inc. The oldest executive at Atricure Inc is Sven Wehrwein, 69, who is the Independent Director.
Michael's mailing address filed with the SEC is 7555, Innovation Way, Innovation Business Center, Mason, Warren County, Ohio, 45040, United States.
Over the last 19 years, insiders at Atricure Inc have traded over $52,789,242 worth of Atricure Inc stock and bought 666,621 units worth $5,937,195 . The most active insiders traders include Scott William Drake, Group I, Llc Donoghue Danie..., and Management Group Viii L L C.... On average, Atricure Inc executives and independent directors trade stock every 24 days with the average trade being worth of $548,410. The most recent stock trade was executed by Maggie Yuen on 15 August 2024, trading 3,500 units of ATRC stock currently worth $84,245.
atricure, inc. provides innovative technologies for the treatment of afib and related conditions. afib affects more than 33 million people worldwide. electrophysiologists and cardiothoracic surgeons around the globe use atricure technologies for the treatment of afib and reduction of afib related complications. atricure’s isolator® synergy™ ablation system is the first and only medical device to receive fda approval for the treatment of persistent afib. atricure’s atriclip left atrial appendage exclusion system products are the most widely sold laa management devices worldwide, with more than 100,000 implanted to date. for more information, visit atricure.com or follow us on twitter @atricure.
Atricure Inc executives and other stock owners filed with the SEC include: